Slide 1: Real-World Innovation
REAL -WORLD INNOVATION AI- first driven discovery platform for multi- parameter small - molecule design April28,2026 1
Slide 2: Forward Looking Statement
FORWARD This presentation contains "forward - looking statements" relating to future events, and Evogene Ltd. (the “Company ”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting are
Slide 3: Evogene Pioneers Real-World Innovation
EVOGENE PIONEERS REAL -WORLD INNOVATION Using a proprietary generative AI engine, we design highly potent and novel small molecules, optimized across -parameters, multiple for the pharmaceutical-chemical and ag industries 3
Slide 4: Our Story
OUR STORY PIONEERING IN PHARMA GEN AI ENGINE REVOLUTIONIZING AG Growing number of ChemPass AI - computational Strategic collaborations for collaborations for diverse engine for the design & ag- chemical development drug targets optimization of small molecules with proven results 4
Slide 5: The Discovery & Optimization Challenge
THE DISCOVERY & OPTIMIZATION CHALLENGE DESIGN THE RIGHT CANDIDATES TO REACH THE MARKET PRODUCT LESS THAN 10%OF PRODUCT CANDIDATE CANDIDATES TESTED IN CLINICAL TRIALS MAKE IT TO MARKET DISCOVERY & OPTIMIZATION TARGET SELECTION EARLY ADVANCED APPROVED (protein) DEVELOPMENT DEVELOPMENT PRODUCT HIT HIT
Slide 6: Novel Chemical Structure & Multi-Parameter Challenge
NOVEL CHEMICAL STRUCTURE & MULTI -PARAMETER CHALLENGE Potency (Binding Affinity) Generating a small molecule with a Solubility novel chemical structure that satisfies all required parameters defining the desired product, while proactively balancing multiple, often competing, criteria. TRADITIONAL ME
Slide 7: Introducing ChemPass AI
NOVELTY - VAST CHEMICAL TERRITORIES based on a 38B- molecule chemical library, the engine designs novel compounds that are synthesizable and active, while accessing unexplored chemical space and creating new IP opportunities INTRODUCING CHEMPASS : AI MULTI -PARAMETER OPTIMIZATION BREAKING CHEMICAL m
Slide 8: ChemPass AI - Design Candidates for Commercial Success
CHEMPASS AI - DESIGN CANDIDATES FOR COMMERCIAL SUCCESS EVOGENE PRODUCT HIGHER PROBABILITY OF CANDIDATE SUCCESS DISCOVERY & OPTIMIZATION TARGET SELECTION EARLY ADVANCED APPROVED (protein) DEVELOPMENT DEVELOPMENT PRODUCT HIT HIT TO LEAD LEAD IDENTIFICATION OPTIMIZATION PHARMA PRECLINICAL CLINICAL AG S
Slide 9: Evogene's Unique Offering
EVOGENE ’S UNIQUE Synthetic Accessibility OFFERING – Potency (Binding Affinity) Chemical Stability PROPRIETARY Solubility Molecular Weight MOLECULAR DESIGN Metabolic Stability A POWERFUL COMBINATION OF CAPABILITIES : IP/Novelty • Novel molecules are generated based on vast and diverse chemical terri
Slide 10: ChemPass AI - Driving Development Success
CHEMPASS AI - DRIVING DEVELOPMENT SUCCESS Step1 Step2 Step3 Result HIT SCREENING HIT TO LEAD LEAD OPTIMIZATION EVOGENE TM PRODUCT CANDIDATE WITHPOINTHIT WITH TM ACTIVESEARCH LEADOP TM WITH GPT Utilizing deep learning to enhance rapid DMTA* coupled with upgraded analog Simultaneous optimization of mu
Slide 11: Technological Collaborations with Google Cloud
TECHNOLOGICAL COLLABORATION S WITH GOOGLE CLOUD FROM GENERATIVE MODELS TO AUTONOMOUS DISCOVERY FIRST COLLABORATION – FIRST -IN-CLASS FOUNDATION MODEL Successful completion of a proprietary generative AI model for novel molecular product candidates addressing multiple parameters, based on 38 billion
Slide 12: Capturing the Business Value of ChemPass AI
CAPTURING THE BUSINESS VALUE CHEMPASS OFAI THROUGH COLLABORATIONS -HOUSE DEVELOPMENT & IN CHEMPASS AI DEVELOPMENT STAGES PARTNERINTERNAL / PIPELINE TARGET Literature search, data PREPROCESSING Target elucidation and biological preprocessing and target modeling interpretation HIT Identify potential h
Slide 13: Our Story
OUR STORY PIONEERING IN PHARMA GEN AI ENGINE REVOLUTIONIZING AG Growing number of ChemPass AI - computational Strategic collaborations for collaborations for diverse engine for the design & ag- chemical development drug targets optimization of small molecules with proven results 13
Slide 14: Growing Opportunity - AI Drug Discovery
PHARMA DIVISION GROWING OPPORTUNITY -DRUGIN DISCOVERY AI Account for AI-based candidates in pipeline Discovery market expected to SMALL 58% >60 $190.68B MOLECULES of total pharmaceutical market 1,344 B) ($ 150 % CAGR in 3last years by2034 14 1) DCAT Value Chain 2) Insights Science Direct 3) Preceden
Slide 15: Collaboration with Systasy Bioscience and LMU
PHARMA DIVISION COLLABORATIONSYSTASY WITH BIOSCIENCE, LUDWIG MAXIMILIAM UNIVERSITY HOSPITAL, MUNICH, GERMANY NOVEL THERAPIES FOR -DERIVED NEUTROPHIL INFLAMMATORY DISEASES • Target : novel mechanism addressing large unmet needs in hyperinflammatory diseases such as inflammatory bowel disease (IBD).
Slide 16: Collaboration with Unravel Biosciences
PHARMA DIVISION COLLABORATION WITH UNRAVEL BIOSCIENCES, BOSTON, USA NOVEL THERAPIES FOR DEMYELINATION DISORDERS • Target : novel mechanism underlying neurodegenerative diseases . • Focused on demyelinating diseases such as MS, representing a global market exceeding $26B*. • Combines ChemPass AI with
Slide 17: Collaboration with Dr. Mark Adams, QUT
PHARMA DIVISION COLLABORATIONDR. WITH MARK ADAMS, QUT, BRISBANE, AUSTRALIA NOVEL THERAPIES FOR CHEMOTHERAPY RESISTANCE IN CANCER TREATMENT • Target : cellular mechanism responsible for resistance to cancer treatments . • Global cancer drug resistance market is estimated at $5.4B in 2025*. • Combines
Slide 18: Collaboration with Prof. Ehud Gazit, TAU
PHARMA DIVISION COLLABORATIONPROF. WITH EHUD GAZIT, TAU, -AVIV,TEL ISRAEL NOVEL THERAPEUTIC MODALITY FOR METABOLIC DISEASES • Target : molecular self- assembly metabolites that underlie metabolic conditions . • Addressable Gout therapeutics market is evaluated at ~$3B*. • Combines ChemPass AI with u
Slide 19: Our Story
OUR STORY PIONEERING IN PHARMA GEN AI ENGINE REVOLUTIONIZING AG Growing number of ChemPass AI - computational Strategic collaborations for collaborations for diverse engine for the design & ag- chemical development drug targets optimization of small molecules with proven results 19
Slide 20: ~$88B Growing Market with Plenty of Room for Innovation
EVOGENE'S SUBSIDIARY ~$88B GROWING MARKET WITH PLENTY OF ROOM FOR INNOVATION $43.3B BROAD SPECTRUM 1 HERBICIDES 1 Increase of pest resistance & regulatory requirements $22.2B FUNGICIDES FOR 2 2 MAJOR DISEASES Urgent need for new Modes of Action ( MoAs) 3 Decreased rate in discovery of new pesticides
Slide 21: Computational Chemistry Can Create Real-World Impact in Agriculture
EVOGENE'S SUBSIDIARY With rising pest resistance, tighter regulation, and laggard development COMPUTATIONAL CHEMISTRY CAN CREATE REAL -WORLD IMPACT IN AGRICULTURE 21
Slide 22: Strategic Collaborations
EVOGENE'S SUBSIDIARY STRATEGIC COLLABORATIONS "Bringing together AgPlenus ’ expertise with Bayer ’s "The collaboration with AgPlenus has CropKey approach to crop protection innovation will accelerated the identification of a class of help accelerate the delivery of essential, sustainable, herbicide
Slide 23: Internal Pipeline - Wheat Blotch
EVOGENE'S SUBSIDIARY INTERNAL PIPELINE APTF -1PRESENTS STRONG POTENTIAL FOR REAL -WORLD INNOVATION WHEAT BLOTCH • Shows clear concentration - dependent antifungal efficacy DISRUPTING1.2 AB$PROBLEM AT RECORD SPEED • Ongoing optimization to • 70% of EU fungicide usage in wheat is for Wheat Blotch 1 en
Slide 24: Internal Pipeline End-to-End Process - Actual Results
EVOGENE'S SUBSIDIARY INTERNAL PIPELINE END -TO-END PROCESS – ACTUAL RESULTS WHEAT BLOTCH PROJECT AGPLENUS BY Step1 Step2 Step3 HIT SCREENING HIT TO LEAD TM LEAD OPTIMIZATION WITH TM POINTHIT WITH ACTIVESEARCH LEADOP TM WITH GPT TARGET PROTEIN New MOA - no available Ordered Ordered Ordered crystallog
Slide 25: Evogene - Real-World Innovation
EVOGENE – REAL -WORLD INNOVATION PHARMA DIVISION – Drugs AG DIVISION* – Ag-Chemicals COLLABORATIONS COLLABORATIONS Neutrophil- Derived Herbicides Inflammatory Diseases Demyelination Disorders Herbicides Lung Cancer INTERNAL PIPELINE Wheat Blotch Metabolic Disease AG DIVISION* – Operations in this fi
Slide 26: Generating Real-World Innovation
HIGH -POTENCY MOLECULES We design highly potent and PIONEERING IN PHARMA AI- first designed molecules novel small molecules, optimized Growing number of optimized through targeted across multiple - parameters, for collaborations addressing experimental validation diverse drug targets for the pharmac
Slide 27: Creating Real-World Innovation for a Better Future
Creating REAL-WORLD INNOVATION for a better future evOgene